Navigation Links
New therapy substitutes missing protein in those with muscular dystrophy
Date:5/26/2009

ng treatment to every muscle cell via gene therapy or stem cells is difficult because muscle tissue makes up such a large portion of the human body. Furthermore, the immune system may reject the cell or gene treatment because patients would treat the newly introduced cells or genes as a foreign substance.

Ervasti's method may conquer both of those problems. Upon injection, the TAT-utrophin combination spreads around the entire body efficiently and is able to penetrate the muscle cell wall to substitute for missing dystrophin. Because every cell in the body makes utrophin naturally, TAT-utrophin circumvents immunity issues associated with other therapeutic approaches.

"Our protein replacement approach most directly and simply addresses the cause of Duchenne muscular dystrophy," Ervasti said.

This new method is not a cure for muscular dystrophy. Rather, it would be a therapy most likely administered on a regular basis. If the treatment works in larger animal models and humans, it's most likely researchers would develop a drug for patients. Ervasti is hopeful the therapy can move into human clinical trials within 3 years.


'/>"/>

Contact: Nick Hanson
hans2853@umn.edu
612-624-2449
University of Minnesota
Source:Eurekalert

Page: 1 2

Related biology news :

1. Gene therapy could expand stem cells promise
2. Breakthrough in radiotherapy promises targeted cancer treatment
3. From cars to cancer: UH professor employs auto industry tools for tumor therapy
4. Hebrew University researchers neutralize tumor growth in embryonic stem cell therapy
5. Moving gene therapy forward with mobile DNA
6. Simulated gene therapy
7. Early administration of antiretroviral therapy can improve survival
8. Stem cell therapy makes cloudy corneas clear, according to Pitt researchers
9. Gene therapy appears safe to regenerate gum tissue
10. Two-day symposium in Baltimore to tackle the promises and perils of proton radiotherapy
11. CSHL team develops mouse models of leukemia that predict response to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
(Date:11/15/2014)... 2014  While we may still be a few years ... "Star Trek" to gain instant access to all that ailed ... smartphones and tablets for monitoring and measuring our health are ... may seem a tad Orwellian to some, but a new ... these technological opportunities into their healthcare regime. These ...
(Date:11/11/2014)...  Forensicon, Inc., a Chicago -based ... the promotion of Yaniv Schiff from Senior ... Schiff,s new role as Director, he will lead company ... examiners and provide leadership within the company,s digital forensics ... Schiff joined Forensicon in 2006 ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... Center have identified how nanoparticles from diesel exhaust damage lung ... for people susceptible to airway disease. The scientists ... the genetic make-up of the affected individual. "We ... in polluted areas and why others don,t," said lead author ...
... young people engage in, has associated adverse health risks ... controlling overall alcohol usage, states an editorial in ... link only) http://www.cmaj.ca/embargo/cmaj110029.pdf . "Given the many ... we need a national strategy for controlling overall alcohol ...
... eating a big breakfast help weight loss or is ... confusing but new research published in BioMed Central,s open ... through these apparently contradictory reports. Dr Volker Schusdziarra, ... study on over 300 people who were asked to ...
Cached Biology News:Findings on pollution damage to human airways could yield new therapies 2
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), ... promotion of Nick Maroulis, Pharm.D. to the newly created ... , In this position, Dr. Maroulis will continue to ... directors of our multi-site pharmacies as the company expands. ... during that time he has served in many different ...
(Date:12/19/2014)... EVANSTON, Ill. , Dec. 19, 2014 ... to develop novel drugs for diseases of the central ... Ph.D., president and chief executive officer, will present at ... Dr. Riedel,s presentation will take place at 3:00 p.m. ... St. Francis in San Francisco, Calif. ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Inc. (Amex:,SGN) announced that it has provided notification to ... withdraw its common stock,from listing and trading on AMEX ... Company Guide. An application to quote and trade Signalife,s ... the OTCBB, on which medium the,shares traded prior to ...
... 8 ThirdBiotech Inc.,( http://www.thirdbiotech.com ), ... today announced that Kemeta, a medical ... manufacture of breath acetone sensing,technology and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070911/LATU119LOGO ), ...
... HARBIN, China, Aug. 8 /Xinhua-PRNewswire-FirstCall/ -- China ... Yingxia" or "the,Company"), a leading provider in ... and distribution of organic nutritional food,products, supplements, ... Republic,of China ("PRC"), announced today it will ...
Cached Biology Technology:Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB 2Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB 3Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB 4ThirdBiotech Announces Kemeta as Newest Sponsor 2China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results 2
...
Bovine Serum...
Healthy animals 10-32 weeks of age, mixed gender and breed; collected on wet ice following USDA guidelines, using Alsevers solution at 1:2 dilution...
... Kits for Sequencing allow 5-minute cloning and subsequent ... Cloning vectors with primer sites located as close ... insertion site. This minimizes the amount of vector ... the sequence of your insert.vectors are available. The ...
Biology Products: